Ennaid Therapeutics Discovers Generic, Oral Pill that May Be Effective Against COVID-19
Ennaid Therapeutics, announced discovery of an existing oral drug that shows strong potential to treat COVID-19. Ennaid has chosen to share the findings of their Proof of Concept Data with the world in hopes that open innovation will accelerate delivery of critically needed therapies across the globe. “The COVID-19 pandemic is the greatest global health challenge we’ve ever faced, so it will take worldwide collaboration to put an end to it,” says Darnisha Grant Harrison, Ennaid CEO-scientist. “We believe it is our moral and ethical responsibility to share our data in light of this second wave of infections.”
Using its artificial intelligence (AI)-based drug discovery platforms, Ennaid’s scientific research team at the Universidad Católica de Murcia (UCAM), in south-eastern Spain, identified . . .
Our Answer to COVID-19
The rationale for developing ENU200 arose from a bioinformatic search for in silico identification of prior-approved chemical compounds blocking the CoV proteins, spike S glycoprotein and Mpro. The results, detailed as follows, suggest the use of ENU200 as a current, viable treatment for COVID-19 and other CoV infections.
Read More400+ Million Infections
Zika virus, a mosquito-borne virus that is explosively spreading, 1.6+ million infections reported, causes microcephaly birth defects. Dengue virus, a life-debilitating, potentially deadly mosquito-borne virus that infects 400 million people, hospitalizes 1.5 million and kills 100,000+ annually.
Anti-Flavivirus
Ennaid Therapeutics is developing an orally deliverable anti-viral peptide that treats and prevents Zika virus and has 9+ additional indications to treat and prevent the following viruses: dengue, chikungunya, West Nile, hepatitis c, yellow fever, tick-borne encephalitis, Japanese encephalitis, European encephalitis, Kyasanur Forest virus.
Strategic Partnerships
We welcome strategic partnerships, as partnerships accelerate the development of our cures from the lab to the people who need them.
Bringing Cures to Life
Ennaid Drug Development
Developing the world’s first therapeutic for Zika virus & all four strains of Dengue virus
Ennaid Healthcare IT
Developing Computer Vision/ Eye tracking software for use in healthcare applications
Ennaid is Dianne (the CEO’s and president’s Mother’s name) spelled backwards.
Dianne means divine/heavenly! Therapeutics means healing solutions.
Ennaid Therapeutics = Divine Healing Solutions
Ennaid Therapeutics affirms the unending presence of healing power and recognizes our path of responsibility as the world’s foremost leader in the sustaining of abundant life. We bring innovative cures to rare and seemingly incurable diseases, thus improving the health and saving the lives of humans and animals all over the world.
Our team of experts
Darnisha Grant Harrison
CEO & President
William J. Brock, Ph.D.
Toxicologist
Romeo Ibrahim
Sr. Process Engineer, Manager of technical & Scientific Affairs, & Scientific Advisory Board
Robert Garry, Ph.D
Chief Scientific Officer, Inventor, & Scientific Advisory Board
Meet The Rest Of Our Superb Team
Message From Our CEO
Darnisha Grant Harrison
President & CEO
“At Ennaid Therapeutics, we recognize the vast amount of good science sitting on research shelves waiting to be positively exploited for use in humans and animals. Therefore, we are committed to translating complex science into today’s cures to help patients live healthier, more abundant lives. We have made great strides as a company and have a promising technology, an accelerated plan and an expert team to develop and commercialize ca cure for Dengue virus..”
We have the technology, the plan and the team to develop & commercialize cures
for Zika Virus and Dengue Virus.